Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomy

Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomy - Safety and efficacy of nab-P + Geme in the patients with recurrent pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031203

Enrollment

Registered

2018-02-09

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

The patients were administered a 30-min intravenous infusion of nab-P (125 mg/m2), followed by a 30-min intravenous Gem 1000 mg/m2), on days 1, 8 and 15, every 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) PDAC patients who diagnosed the recurrent pancreatic cancer on multidetector-row CT. 2) Age (20 years old or more and 85 years old or less) 3) Performance Status (ECOG): 0 or 1 4) Agreement of the subject after informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with allergy for nab-paclitaxel and gemcitabine 2) Patients with severe infection 3) Patients who are considered to be inappropriate for this study

Design outcomes

Primary

Measure	Time frame
The safety and efficacy of the combination therapy with nab-paclitaxel plus gemcitabine in the patients with recurrent PC.	—

Secondary

Measure	Time frame
disease control rate	—

Countries

Japan

Contacts

Public ContactHiromichi Kawaida

Faculty of Medicine,University of Yamanashi First Department of Surgery

kawaidah@yamanashi.ac.jp055-273-7390

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026